Iovance Biotherapeutics

Health Canada granted conditional marketing authorization for AMTAGVI, marking the first T-cell therapy approved for solid tumors in Canada, specifically for advanced melanoma treatment.

Iovance Biotherapeutics voluntarily withdrew its European Union regulatory filing for Amtagvi due to lack of alignment with the EMA on clinical data supporting the submission.

Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.

Iovance Biotherapeutics achieved $60.0 million in total product revenue for Q2 2025, representing a 93% year-over-year increase driven by strong Amtagvi adoption.

Iovance Biotherapeutics is reducing its workforce by less than 20% in a strategic restructuring following disappointing commercial performance of its TIL cell therapy Amtagvi.

Iovance Biotherapeutics shares surged 14.46% in pre-market trading following FDA approval of its cancer treatment Amtagvi and positive clinical trial results.

Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.

Iovance Biotherapeutics has appointed Marc R. Theoret, M.D., former FDA Deputy Center Director, to the newly created position of Senior Vice President, Regulatory Strategy.

Iovance Biotherapeutics CFO Jean-Marc Bellemin resigned effective July 10, 2025, following significant commercial setbacks for the company's melanoma treatment Amtagvi.

UBS analysts downgraded Iovance shares from Buy to Neutral and slashed price target from $17 to $2, citing concerns over Amtagvi's commercial rollout and operational challenges.